Cas:188661-09-8 Trithiocyanuric acid trisodium salt hydrate manufacturer & supplier

Chemical Name:Trithiocyanuric acid trisodium salt hydrate

CAS.NO:188661-09-8

Synonyms:Trithiocyanuric acid trisodium salt hydrate

Molecular Formula:C₃H₃N₃S₃Na₃·xH₂O

Molecular Weight:243.22

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Trithiocyanuric acid trisodium salt hydrate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Trithiocyanuric acid trisodium salt hydrate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Trithiocyanuric acid trisodium salt hydrate Use and application,Trithiocyanuric acid trisodium salt hydrate technical grade,usp/ep/jp grade.

Related News: In the current trial, a total of 196 patients were randomly chosen to receive either the vaccine or a placebo. Trithiocyanuric acid trisodium salt hydrate manufacturer Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit,�� Shanghai Green Valley Pharmaceuticals, which developed the drug along with two academic institutions in China, said in a statement. Trithiocyanuric acid trisodium salt hydrate supplier Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs. Trithiocyanuric acid trisodium salt hydrate vendor Like other countries in Southeast Asia, Indonesia depends heavily on Chinese tourism. On Thursday alone, 10,000 Chinese tourists canceled their trips to Bali, according to one industry association. Trithiocyanuric acid trisodium salt hydrate factory Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit,�� Shanghai Green Valley Pharmaceuticals, which developed the drug along with two academic institutions in China, said in a statement.